About Small Pharma
Small Pharma is a company based in London (United Kingdom) founded in 2015 was acquired by Cybin in August 2023. Small Pharma has raised $49.17 million across 7 funding rounds from investors including Gov.uk, Canaccord Genuity Group and Cybin. The company has 9 employees as of February 28, 2021. Small Pharma offers products and services including CYB003 and CYB004. Small Pharma operates in a competitive market with competitors including GH Research, Lykos and Ketabon, among others.
- Headquarter London, United Kingdom
- Employees 9 as on 28 Feb, 2021
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Small Pharma Ltd
-
Annual Revenue
$58.28 K (USD)-52as on Feb 28, 2021
-
Net Profit
-$13.74 M (USD)-145as on Feb 28, 2022
-
EBITDA
-$14.26 M (USD)-155as on Feb 28, 2022
-
Total Equity Funding
$49.17 M (USD)
in 7 rounds
-
Latest Funding Round
$46.02 M (USD), Series A
Mar 09, 2021
-
Investors
Gov.uk
& 8 more
-
Employee Count
9
as on Feb 28, 2021
-
Acquired by
Cybin
(Aug 28, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Small Pharma
Small Pharma offers a comprehensive portfolio of products and services, including CYB003 and CYB004.
Targets Major Depressive Disorder through psychedelic innovation
Addresses Generalized Anxiety Disorder via novel formulations
Funding Insights of Small Pharma
Small Pharma has successfully raised a total of $49.17M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $46.02 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Small Pharma
Small Pharma has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Gov.uk, Canaccord Genuity Group and Cybin.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
AI Fund is operated as a venture studio for AI startups.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on angel investments
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Small Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Small Pharma
Investment portfolio details for Small Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Small Pharma
Detailed financials for Small Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Small Pharma Comparisons
Peer comparison for Small Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Small Pharma
Small Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GH Research, Lykos and Ketabon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for mental disease management are developed using 5-MeO-DMT formulations.
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat mental health conditions
|
|
| Locked | Locked | Locked |
Develops innovative therapeutics for treatment-resistant depression.
|
Detailed competitors of Small Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Small Pharma
Complete news archive for Small Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Small Pharma
Small Pharma was founded in 2015.
Small Pharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Small Pharma is a funded company, having raised a total of $49.17M across 7 funding rounds to date.
As of Feb 28, 2021, the latest employee count at Small Pharma is 9.
Annual revenue of Small Pharma is $58.28K as on Feb 28, 2021.
Small Pharma was founded in 2015 in London, United Kingdom. Psychedelic-based therapeutics targeting mental health conditions are developed within the biotechnology sector. Tryptamine-based drug candidates are formulated using proprietary deuterium enriching technology. Operations center on advancing the pipeline, which includes SPL026, SPL028, SPL029, and SPL801 as injectable and oral DMT therapies for depressive disorder.
Small Pharma's top competitors include GH Research, Lykos and Ketabon.
Small Pharma offers CYB003 and CYB004.
Small Pharma has 9 investors. Key investors include Gov.uk, Canaccord Genuity Group, Cybin, AI Fund, and o2h ventures.
The valuation of Small Pharma is $4.19M as of Jul 2019.